Company / Revenue per Share
Lineage Cell Therapeutics, Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.07
FY2025
5-year range
$0.01 / $0.07
FY2021-FY2025
Trend
+21.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue per Share has increased for 4 consecutive years, from $0.01 in FY2021 to $0.07 in FY2025.
Based on SEC 10-K filings.
0.07 in FY2025 with a 5-year CAGR of +23.0%.
Improved from $0.05 to $0.07 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +37.1%
- 5-Year CAGR
- +23.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Lineage Cell Therapeutics, Inc.'s revenue per share has grown for 4 consecutive years.
- In FY2025, revenue per share increased 21.7% year-over-year.
- Peak revenue per share was recorded in FY2017.
- Lowest revenue per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.07 | +21.7% |
| FY2024 | $0.05 | +3.2% |
| FY2023 | $0.05 | +105.3% |
| FY2022 | $0.03 | +114.8% |
| FY2021 | $0.01 | -49.2% |
| FY2020 | $0.02 | -40.2% |
| FY2019 | $0.04 | +43.9% |
| FY2018 | $0.03 | -60.2% |
| FY2017 | $0.07 | +18.0% |
| FY2016 | $0.06 | +2.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026